LGT Fund Management Co Ltd. Trims Stock Position in Boston Scientific Corporation $BSX

Key Points

• LGT Fund Management Co Ltd. reduced its stake in Boston Scientific by 10%, now holding 52,466 shares worth approximately $5.6 million.
• Several other hedge funds have shown increased interest, with Bank of New Hampshire boosting its position by 552%, now owning 19,724 shares valued at around $2.1 million.
• Analyst ratings have generally improved, with Wells Fargo and UBS Group raising their price targets for Boston Scientific, indicating positive sentiment among financial analysts.

LGT Fund Management Co Ltd. lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 10.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,466 shares of the medical equipment provider's stock after selling 5,838 shares during the quarter. LGT Fund Management Co Ltd.'s holdings in Boston Scientific were worth $5,635,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock worth $3,167,000 after acquiring an additional 3,932 shares in the last quarter. Bank of New Hampshire boosted its position in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock valued at $2,119,000 after acquiring an additional 16,699 shares during the last quarter. MRA Advisory Group bought a new stake in Boston Scientific in the second quarter worth $273,000. NS Partners Ltd lifted its position in Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after buying an additional 5,704 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. lifted its position in Boston Scientific by 95.9% in the second quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock worth $4,883,000 after buying an additional 22,255 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on BSX. Wells Fargo & Company raised their price target on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. UBS Group raised their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Oppenheimer raised Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Erste Group Bank downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $120.79.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

NYSE:BSX opened at $97.30 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The company has a 50 day moving average price of $102.93 and a 200-day moving average price of $102.05. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.